RU2642463C2 - Циклопропанкарбоксилатные эфиры пуриновых аналогов - Google Patents

Циклопропанкарбоксилатные эфиры пуриновых аналогов Download PDF

Info

Publication number
RU2642463C2
RU2642463C2 RU2014145481A RU2014145481A RU2642463C2 RU 2642463 C2 RU2642463 C2 RU 2642463C2 RU 2014145481 A RU2014145481 A RU 2014145481A RU 2014145481 A RU2014145481 A RU 2014145481A RU 2642463 C2 RU2642463 C2 RU 2642463C2
Authority
RU
Russia
Prior art keywords
compound
amino
alkyl
oxo
dihydropurin
Prior art date
Application number
RU2014145481A
Other languages
English (en)
Russian (ru)
Other versions
RU2014145481A (ru
Inventor
Цзи-Ван ЧЭРН
Шинь-Юй ЛАЙ
Пэй-Тэх ЧАН
Original Assignee
Аннцзи Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аннцзи Фармасьютикал Ко., Лтд. filed Critical Аннцзи Фармасьютикал Ко., Лтд.
Publication of RU2014145481A publication Critical patent/RU2014145481A/ru
Application granted granted Critical
Publication of RU2642463C2 publication Critical patent/RU2642463C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
RU2014145481A 2012-04-20 2013-04-02 Циклопропанкарбоксилатные эфиры пуриновых аналогов RU2642463C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261635931P 2012-04-20 2012-04-20
US61/635,931 2012-04-20
PCT/US2013/035042 WO2013158367A1 (en) 2012-04-20 2013-04-02 Cyclopropanecarboxylate esters of purine analogues

Publications (2)

Publication Number Publication Date
RU2014145481A RU2014145481A (ru) 2016-06-10
RU2642463C2 true RU2642463C2 (ru) 2018-01-25

Family

ID=49380678

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014145481A RU2642463C2 (ru) 2012-04-20 2013-04-02 Циклопропанкарбоксилатные эфиры пуриновых аналогов
RU2014145480A RU2627706C2 (ru) 2012-04-20 2013-04-03 Производные индолин-2-она в качестве ингибиторов протеинкиназ

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014145480A RU2627706C2 (ru) 2012-04-20 2013-04-03 Производные индолин-2-она в качестве ингибиторов протеинкиназ

Country Status (13)

Country Link
US (2) US8969361B2 (enExample)
EP (2) EP2838538B1 (enExample)
JP (2) JP6177879B2 (enExample)
KR (2) KR101774861B1 (enExample)
CN (2) CN104394868A (enExample)
AU (2) AU2013249708B2 (enExample)
BR (1) BR112014026182A2 (enExample)
ES (2) ES2621257T3 (enExample)
IL (2) IL235097A (enExample)
IN (2) IN2014MN02105A (enExample)
RU (2) RU2642463C2 (enExample)
TW (2) TWI496784B (enExample)
WO (2) WO2013158367A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
HUE050083T2 (hu) * 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
EP4267642B1 (de) 2020-12-23 2026-06-24 Basf Se Neuer katalysator zur herstellung von polyurethanen
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CN113999221B (zh) * 2021-11-04 2024-04-05 南京中医药大学 6-位取代的吲哚酮衍生物及其医药用途
CN114380802B (zh) * 2022-01-07 2023-11-17 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用
WO2024110395A1 (de) 2022-11-24 2024-05-30 Basf Se Verbesserung der lagerstabilität von hydrofluorolefinen in aminhaltigen polyolkomponenten für die herstellung von polyurethanen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
US20080146591A1 (en) * 2006-12-13 2008-06-19 Maria Oksana Bachynsky Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride
WO2009111739A2 (en) * 2008-03-07 2009-09-11 Exley Ray W Treatment of herpes virus related diseases
US20090270428A1 (en) * 2005-05-25 2009-10-29 David Michael Bender Cyclopropanecarboxylate esters of acyclovir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT351865B (de) 1977-04-01 1979-08-27 Hoffmann La Roche Akarizide mittel
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
MXPA06004438A (es) 2003-10-24 2006-06-20 Schering Ag Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
CA2621809A1 (en) 2005-09-22 2007-04-05 The Scripps Research Institute Alkoxy indolinone based protein kinase inhibitors
CN1850794A (zh) * 2006-05-30 2006-10-25 中国医学科学院医药生物技术研究所 3－酰胺基取代苯甲酰脲类化合物及其抗肿瘤作用
KR20090092317A (ko) 2006-12-11 2009-08-31 아이알엠 엘엘씨 키나제 억제제로서의 화합물 및 조성물
CA2690569A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
US7846793B2 (en) 2007-10-03 2010-12-07 Applied Materials, Inc. Plasma surface treatment for SI and metal nanocrystal nucleation
EP2274311A2 (en) * 2008-03-28 2011-01-19 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and methods for the treatment of viral infection
PE20100087A1 (es) * 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
RU2011103189A (ru) * 2008-06-30 2012-08-10 Силин Фармасьютикалз, Инк. (Us) Производные оксиндола
US20100298376A1 (en) 2009-05-13 2010-11-25 Board Of Regents, The University Of Texas System Use of novel neuroprotective 3-substituted indolone compositions
GB201014374D0 (en) 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
CN103179966B (zh) * 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
US20090270428A1 (en) * 2005-05-25 2009-10-29 David Michael Bender Cyclopropanecarboxylate esters of acyclovir
US20080146591A1 (en) * 2006-12-13 2008-06-19 Maria Oksana Bachynsky Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride
RU2440118C2 (ru) * 2006-12-13 2012-01-20 Ф.Хоффманн-Ля Рош Аг Порошкообразный препарат валганцикловира
WO2009111739A2 (en) * 2008-03-07 2009-09-11 Exley Ray W Treatment of herpes virus related diseases
US20110112117A1 (en) * 2008-03-07 2011-05-12 Ray W Exley Treatment of herpes virus related diseases

Also Published As

Publication number Publication date
JP6177879B2 (ja) 2017-08-09
JP2015514762A (ja) 2015-05-21
EP2838531A1 (en) 2015-02-25
KR20150005600A (ko) 2015-01-14
RU2014145481A (ru) 2016-06-10
RU2627706C2 (ru) 2017-08-10
KR101778095B1 (ko) 2017-09-13
CN104302287B (zh) 2017-12-26
US8969361B2 (en) 2015-03-03
TW201343627A (zh) 2013-11-01
AU2013249714B2 (en) 2016-12-15
US20130281517A1 (en) 2013-10-24
WO2013158367A1 (en) 2013-10-24
BR112014026182A2 (pt) 2017-06-27
EP2838538A1 (en) 2015-02-25
AU2013249714A1 (en) 2014-11-13
IN2014MN02107A (enExample) 2015-09-11
AU2013249708A1 (en) 2014-11-13
RU2014145480A (ru) 2016-06-10
IL235097A (en) 2017-07-31
CN104302287A (zh) 2015-01-21
JP2015514761A (ja) 2015-05-21
EP2838538A4 (en) 2015-09-02
TWI496784B (zh) 2015-08-21
WO2013158373A8 (en) 2014-10-30
CN104394868A (zh) 2015-03-04
TW201350485A (zh) 2013-12-16
EP2838531B1 (en) 2016-09-21
WO2013158373A1 (en) 2013-10-24
KR101774861B1 (ko) 2017-09-05
IN2014MN02105A (enExample) 2015-09-11
KR20150005630A (ko) 2015-01-14
AU2013249708B2 (en) 2017-03-16
EP2838531A4 (en) 2015-12-16
IL235098A0 (en) 2014-12-31
US20130281451A1 (en) 2013-10-24
EP2838538B1 (en) 2017-03-15
TWI458709B (zh) 2014-11-01
US8946282B2 (en) 2015-02-03
ES2621257T3 (es) 2017-07-03
ES2600467T3 (es) 2017-02-09
JP6174119B2 (ja) 2017-08-02

Similar Documents

Publication Publication Date Title
JP6177879B2 (ja) プリンアナログのシクロプロパンカルボキシレートエステル
DK170803B1 (da) 2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-ethyl-L-isoleucinat og salte heraf, disse forbindelsers anvendelse inden for medicinsk terapi, og farmaceutisk komposition indeholdende en sådan forbindelse
WO2017216054A1 (en) Dihydropyrimidinyl benzazepine carboxamide compounds
DK159444B (da) Analogifremgangsmaade til fremstilling af derivater af 9-(2-hydroxyethoxymethyl)guanin
JP6280912B2 (ja) 複素環化合物
CN108349981A (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
CN116574105B (zh) 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
JP2005089334A (ja) ８−ヒドロキシアデニン化合物
CN113444105A (zh) 一种Relugolix的制备方法
WO2012109423A1 (en) Method of inhibiting hamartoma tumor cells
US11827640B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators
AU2007218725B2 (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
EA031334B1 (ru) Амиды 2-амино-4-арилтиазольных соединений и их соли
CA2583920C (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
CN113880772A (zh) 一类cdk激酶抑制剂及其应用
CN115073518B (zh) 磷酸双依达拉奉酯类化合物、及其制备方法和用途
RU2431632C2 (ru) Производные хиназолина
WO2003095435A1 (en) Amide derivatives
CN117229223A (zh) 一种杂环衍生物及其药物组合物、应用
JPH06263754A (ja) ７−アミノピロリジニルキノリン−３−カルボン酸誘導体
JP6750177B2 (ja) アントラニルアミド誘導体およびそれを含有するｔｌｒ３が関与する疾患の治療剤
JPH0649059A (ja) ７−（５−アザスピロ〔２，４〕ヘプタン−５−イル）−８−アルコキシキノリン−３−カルボン酸誘導体
CN113583022A (zh) 多环化合物及其药物组合物和用途
JP2004026818A (ja) アミド誘導体又はその塩
JPH06107657A (ja) ５−メチルキノリン−３−カルボン酸誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190403